IGI Logo

Key MeetingTakeaways

Ophthalmic products:

* The company has 13-14 Ophthalmic ANDAs pending for approval (market size of USD1800mn), The company expects 4- 5 of these to be launched in FY23 (marker size of USD650mn) and it will have an early launch advantage in 3 of those products. Rest 9 would be launched in FY24.

Domestic formulations:

* Company witnessing operational costs returning to pre-covid levels.

* Launched two products in Q1FY22– Naricover Lozenges 10s (under the Respiratory segment) and Methycal 60K, 4s Tablets (under Vitamin /Mineral / Nutrients segment).

Change in market strategy:

* Management highlighted the intent to increase market share in anti-infective, anti-cold, paediatric, gynaecology segments.

Vision:

* To achieve Rs500cr EBIDTA by FY24/FY25 driven by new products in domestic business, excellent product pipeline in the US business and high growth opportunity in Europe market.

US biz growth:

* Strategy to focus on solids, injectables and suspension ophthalmic in the niche and complex products.

API Business:

* Capacity utilization stands at 60-65%. Company to incur capex on new manufacturing capacities (1 dozen reactors); work to commence post monsoon and it expects 25-30% capacity expansion. Acquired a plot in the vicinity wherein it will set up a manufacturing block as well as a warehouse; to add ~50% capacity to the existing base.

CRO business:

* The company expects increased possibility higher of launches on the front end side in the US/ higher rate of dossier filing

To Read Complete Report & Disclaimer Click Here

Please refer disclaimer at  https://www.mnclgroup.com/disclaimer

SEBI Registration Number : INZ000043833

Above views are of the author and not of the website kindly read disclaimer